OTCM
BIMI
Market cap1kUSD
Jul 08, Last price
0.00USD
1D
0.00%
1Q
-99.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Bimi International Medical Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BIMI International Medical Inc., headquartered in Chongqing, China, is an enterprise engaged in a diverse array of healthcare operations. The company, which was established in 2000 and adopted its current name in June 2021 (formerly BOQI International Medical Inc.), focuses on the supply and sale of medical devices, pharmaceuticals, and other health-related products. Its business activities are structured across four main divisions: wholesale pharmaceuticals, wholesale medical devices, medical services, and retail pharmacies. For its wholesale segment, BIMI distributes a wide range of specialized medical equipment, including Stryker spinal products, Olympus endoscopes, various imported imaging devices, and diagnostic imaging systems. These products are supplied to clients such as drugstores, private clinics, pharmaceutical dealers, and hospitals, particularly within China's Southwest region. The company also facilitates the distribution of a broad spectrum of pharmaceutical products, comprising generic medications, traditional Chinese herbal remedies, biochemical drugs, essential raw ingredients for pharmaceuticals, antibiotics, cardiovascular treatments, and anti-obesity medicines. Through its "Lijiantang Pharmacy" brand, BIMI operates a network of directly-owned retail outlets. These pharmacies offer consumers an extensive selection of items, including prescription and over-the-counter drugs, nutritional supplements, health foods, sundry goods, traditional Chinese medicines, personal and family care products, and medical devices. Beyond product sales, BIMI also delivers medical services within hospital environments and undertakes IT research and development initiatives.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||